231 related articles for article (PubMed ID: 18295466)
1. Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy.
Fogarasi M; Janssen A; Weber BH; Stöhr H
Matrix Biol; 2008 Jun; 27(5):381-92. PubMed ID: 18295466
[TBL] [Abstract][Full Text] [Related]
2. Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis.
Soboleva G; Geis B; Schrewe H; Weber BH
J Cell Physiol; 2003 Oct; 197(1):149-56. PubMed ID: 12942551
[TBL] [Abstract][Full Text] [Related]
3. Deglycosylation Increases the Aggregation and Angiogenic Properties of Mutant Tissue Inhibitor of Metalloproteinase 3 Protein: Implications for Sorsby Fundus Dystrophy.
Qi JH; Anand-Apte B
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430707
[TBL] [Abstract][Full Text] [Related]
4. Sorsby fundus dystrophy - A review of pathology and disease mechanisms.
Christensen DRG; Brown FE; Cree AJ; Ratnayaka JA; Lotery AJ
Exp Eye Res; 2017 Dec; 165():35-46. PubMed ID: 28847738
[TBL] [Abstract][Full Text] [Related]
5. A mouse model for Sorsby fundus dystrophy.
Weber BH; Lin B; White K; Kohler K; Soboleva G; Herterich S; Seeliger MW; Jaissle GB; Grimm C; Reme C; Wenzel A; Asan E; Schrewe H
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2732-40. PubMed ID: 12147610
[TBL] [Abstract][Full Text] [Related]
6. In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby fundus dystrophy.
Hongisto H; Dewing JM; Christensen DR; Scott J; Cree AJ; Nättinen J; Määttä J; Jylhä A; Aapola U; Uusitalo H; Kaarniranta K; Ratnayaka JA; Skottman H; Lotery AJ
J Pathol; 2020 Oct; 252(2):138-150. PubMed ID: 32666594
[TBL] [Abstract][Full Text] [Related]
7. TIMP3, angiogenesis and macular degeneration.
Matrix Biol; 2008 Jun; 27(5):379-80. PubMed ID: 18571611
[No Abstract] [Full Text] [Related]
8. Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism.
Qi JH; Bell B; Singh R; Batoki J; Wolk A; Cutler A; Prayson N; Ali M; Stoehr H; Anand-Apte B
Sci Rep; 2019 Nov; 9(1):17429. PubMed ID: 31757977
[TBL] [Abstract][Full Text] [Related]
9. Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3.
Janssen A; Hoellenriegel J; Fogarasi M; Schrewe H; Seeliger M; Tamm E; Ohlmann A; May CA; Weber BH; Stöhr H
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):2812-22. PubMed ID: 18408187
[TBL] [Abstract][Full Text] [Related]
10. S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis.
Qi JH; Dai G; Luthert P; Chaurasia S; Hollyfield J; Weber BH; Stöhr H; Anand-Apte B
J Biol Chem; 2009 Jul; 284(30):19927-36. PubMed ID: 19478078
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond.
Naessens S; De Zaeytijd J; Syx D; Vandenbroucke RE; Smeets F; Van Cauwenbergh C; Leroy BP; Peelman F; Coppieters F
Hum Mutat; 2019 May; 40(5):539-551. PubMed ID: 30668888
[TBL] [Abstract][Full Text] [Related]
12. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2.
Wang WM; Ge G; Lim NH; Nagase H; Greenspan DS
Biochem J; 2006 Sep; 398(3):515-9. PubMed ID: 16771712
[TBL] [Abstract][Full Text] [Related]
13. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy.
Lin RJ; Blumenkranz MS; Binkley J; Wu K; Vollrath D
Am J Ophthalmol; 2006 Nov; 142(5):839-48. PubMed ID: 16989765
[TBL] [Abstract][Full Text] [Related]
14. Sorsby fundus dystrophy: Insights from the past and looking to the future.
Anand-Apte B; Chao JR; Singh R; Stöhr H
J Neurosci Res; 2019 Jan; 97(1):88-97. PubMed ID: 30129971
[TBL] [Abstract][Full Text] [Related]
15. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension.
Basu R; Lee J; Morton JS; Takawale A; Fan D; Kandalam V; Wang X; Davidge ST; Kassiri Z
Cardiovasc Res; 2013 Jun; 98(3):360-71. PubMed ID: 23524300
[TBL] [Abstract][Full Text] [Related]
16. TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights.
Li Z; Clarke MP; Barker MD; McKie N
Expert Rev Mol Med; 2005 Oct; 7(24):1-15. PubMed ID: 16259644
[TBL] [Abstract][Full Text] [Related]
17. Role of FGF and Hyaluronan in Choroidal Neovascularization in Sorsby Fundus Dystrophy.
Wolk A; Hatipoglu D; Cutler A; Ali M; Bell L; Hua Qi J; Singh R; Batoki J; Karle L; Bonilha VL; Wessely O; Stoehr H; Hascall V; Anand-Apte B
Cells; 2020 Mar; 9(3):. PubMed ID: 32143276
[TBL] [Abstract][Full Text] [Related]
18. Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis.
Qi JH; Ebrahem Q; Yeow K; Edwards DR; Fox PL; Anand-Apte B
J Biol Chem; 2002 Apr; 277(16):13394-400. PubMed ID: 11821400
[TBL] [Abstract][Full Text] [Related]
19. Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients.
Arris CE; Bevitt DJ; Mohamed J; Li Z; Langton KP; Barker MD; Clarke MP; McKie N
Biochim Biophys Acta; 2003 May; 1638(1):20-8. PubMed ID: 12757930
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa.
Fariss RN; Apte SS; Luthert PJ; Bird AC; Milam AH
Br J Ophthalmol; 1998 Nov; 82(11):1329-34. PubMed ID: 9924344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
